Susquehanna International Group’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $935K | Sell |
304,400
-60,100
| -16% | -$260K | ﹤0.01% | 8047 |
|
|
2025
Q4 | $1.3M | Sell |
364,500
-332,900
| -48% | -$2.04M | ﹤0.01% | 6590 |
|
|
2025
Q3 | $6.21M | Buy |
697,400
+406,400
| +140% | +$4.12M | ﹤0.01% | 3746 |
|
|
2025
Q2 | $2.68M | Sell |
291,000
-96,600
| -25% | -$825K | ﹤0.01% | 5184 |
|
|
2025
Q1 | $3.33M | Buy |
387,600
+109,700
| +39% | +$1.04M | ﹤0.01% | 4446 |
|
|
2024
Q4 | $2.98M | Buy |
277,900
+89,300
| +47% | +$687K | ﹤0.01% | 4484 |
|
|
2024
Q3 | $1.07M | Buy |
188,600
+67,000
| +55% | +$387K | ﹤0.01% | 6633 |
|
|
2024
Q2 | $513K | Sell |
121,600
-139,200
| -53% | -$563K | ﹤0.01% | 8202 |
|
|
2024
Q1 | $1.33M | Sell |
260,800
-387,500
| -60% | -$2.18M | ﹤0.01% | 6248 |
|
|
2023
Q4 | $6.04M | Buy |
648,300
+160,300
| +33% | +$1.1M | ﹤0.01% | 3401 |
|
|
2023
Q3 | $3.2M | Buy |
488,000
+45,000
| +10% | +$358K | ﹤0.01% | 4267 |
|
|
2023
Q2 | $3.6M | Sell |
443,000
-56,200
| -11% | -$482K | ﹤0.01% | 4057 |
|
|
2023
Q1 | $4.28M | Sell |
499,200
-187,000
| -27% | -$1.87M | ﹤0.01% | 3681 |
|
|
2022
Q4 | $6.35M | Buy |
686,200
+77,200
| +13% | +$825K | ﹤0.01% | 2876 |
|
|
2022
Q3 | $6.29M | Buy |
609,000
+86,200
| +16% | +$910K | ﹤0.01% | 2818 |
|
|
2022
Q2 | $5.23M | Buy |
522,800
+193,100
| +59% | +$1.83M | ﹤0.01% | 3115 |
|
|
2022
Q1 | $4.06M | Sell |
329,700
-52,000
| -14% | -$639K | ﹤0.01% | 4029 |
|
|
2021
Q4 | $6.62M | Buy |
381,700
+46,400
| +14% | +$882K | ﹤0.01% | 3298 |
|
|
2021
Q3 | $6.02M | Sell |
335,300
-341,600
| -50% | -$6.8M | ﹤0.01% | 3625 |
|
|
2021
Q2 | $15.5M | Buy |
676,900
+308,800
| +84% | +$4.57M | ﹤0.01% | 2341 |
|
|
2021
Q1 | $5.5M | Buy |
368,100
+90,800
| +33% | +$992K | ﹤0.01% | 3720 |
|
|
2020
Q4 | $1.5M | Sell |
277,300
-7,300
| -3% | -$38.5K | ﹤0.01% | 5747 |
|
|
2020
Q3 | $1.29M | Sell |
284,600
-145,600
| -34% | -$627K | ﹤0.01% | 5507 |
|
|
2020
Q2 | $2.12M | Sell |
430,200
-31,500
| -7% | -$119K | ﹤0.01% | 4390 |
|
|
2020
Q1 | $1.45M | Buy |
461,700
+131,700
| +40% | +$459K | ﹤0.01% | 4562 |
|
|
2019
Q4 | $855K | Buy |
330,000
+46,400
| +16% | +$122K | ﹤0.01% | 5834 |
|
|
2019
Q3 | $896K | Buy |
283,600
+96,000
| +51% | +$277K | ﹤0.01% | 5914 |
|
|
2019
Q2 | $632K | Buy |
187,600
+92,900
| +98% | +$289K | ﹤0.01% | 6754 |
|
|
2019
Q1 | $289K | Sell |
94,700
-36,100
| -28% | -$86.2K | ﹤0.01% | 7281 |
|
|
2018
Q4 | $204K | Sell |
130,800
-111,100
| -46% | -$252K | ﹤0.01% | 7709 |
|
|
2018
Q3 | $660K | Buy |
241,900
+104,700
| +76% | +$295K | ﹤0.01% | 6031 |
|
|
2018
Q2 | $359K | Buy |
137,200
+26,000
| +23% | +$72.6K | ﹤0.01% | 7481 |
|
|
2018
Q1 | $307K | Sell |
111,200
-2,500
| -2% | -$7.06K | ﹤0.01% | 7598 |
|
|
2017
Q4 | $366K | Sell |
113,700
-900
| -0.8% | -$3.54K | ﹤0.01% | 7220 |
|
|
2017
Q3 | $474K | Sell |
114,600
-33,900
| -23% | -$151K | ﹤0.01% | 6609 |
|
|
2017
Q2 | $790K | Sell |
148,500
-2,100
| -1% | -$12.1K | ﹤0.01% | 5755 |
|
|
2017
Q1 | $864K | Sell |
150,600
-29,300
| -16% | -$151K | ﹤0.01% | 5437 |
|
|
2016
Q4 | $712K | Sell |
179,900
-36,100
| -17% | -$129K | ﹤0.01% | 6244 |
|
|
2016
Q3 | $784K | Buy |
216,000
+104,300
| +93% | +$439K | ﹤0.01% | 5251 |
|
|
2016
Q2 | $682K | Buy |
111,700
+53,300
| +91% | +$257K | ﹤0.01% | 5577 |
|
|
2016
Q1 | $286K | Buy |
58,400
+4,100
| +8% | +$18K | ﹤0.01% | 7334 |
|
|
2015
Q4 | $302K | Buy |
+54,300
| New | +$386K | ﹤0.01% | 7672 |
|
Other funds holding AVXL
VCM
SF
VPM
Susquehanna International Group's AVXL Position: Q1 2026 in Review
Susquehanna International Group increased its Anavex Life Sciences (AVXL) stake by 127% in Q1 2026, buying an estimated $2.41M and bringing the position to 995,663 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #5235.
Susquehanna International Group first reported a position in AVXL in Q4 2015 and has held it in 42 quarters since. The position peaked at $15.7M in Q2 2021. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.
- Susquehanna International Group held 995,663 shares of Anavex Life Sciences worth $3.06M as of Q1 2026.
- Susquehanna International Group bought 556,164 Anavex Life Sciences shares in Q1 2026, an estimated $2.41M.
- Anavex Life Sciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5235 holding.
- Susquehanna International Group first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 42 quarters since.
- Susquehanna International Group's Anavex Life Sciences position peaked at $15.7M in Q2 2021.
- 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.